Research programme: anticancer therapeutics - MedImmune/AmgenAlternative Names: cMET Avimer™ antagonist - MedImmune/Amgen; cMET-targeted therapeutics - MedImmune/Amgen; MEDI-555
Latest Information Update: 11 Dec 2009
At a glance
- Originator Amgen; MedImmune
- Mechanism of Action Proto oncogene protein c met inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer